| h-var-c0ea5a3d50 | Distinct J-protein architectures decode exposed β-sheet recognition codes to ena | 0.48 | 0.35 | DNAJB6 | proposed | 2026-04-27 | SDA-2026-04-10-gap-debate-20260410-075012-32bac138 |
| h-var-c60fc47c34 | Parthenolide enhances ADORA2A receptor internalization through direct sesquiterp | 0.48 | 0.40 | ADORA2A | proposed | 2026-04-27 | SDA-2026-04-26-gap-pubmed-20260410-193037-1dc5e03a-debate |
| h-43a8ab92dd | SIRT3 gates microglial surveillance versus primed metabolism through mitochondri | 0.48 | 0.38 | SIRT3 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062033-839c3e2a |
| h-d78123d1 | Microglia-Derived Extracellular Vesicle Engineering for Targeted Mitochondrial D | 0.48 | 0.30 | RAB27A/LAMP2B | archived | 2026-04-03 | SDA-2026-04-01-gap-20260401231108 |
| h-fa079a4295 | Isoform-Selective Hsp70 Targeting Overcomes Stoichiometric Imbalance in Advanced | 0.48 | 0.55 | HSPA1A, DNAJB6, DNAJB8 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062052-28cbc764 |
| hyp-sda-2026-04-01-0 | FCER1G-Mediated Alternative Immune Signaling | 0.48 | 0.50 | ['FCER1G'] | active | 2026-04-28 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | Soluble TREM2 Sequestration and Recycling | 0.48 | 0.50 | ['TREM2'] | active | 2026-04-28 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | SIRPA-Mediated Microglial Disinhibition | 0.48 | 0.50 | ['SIRPA'] | active | 2026-04-28 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | TYROBP-SYK Pathway Enhancement | 0.48 | 0.50 | ['TYROBP', 'SYK'] | active | 2026-04-28 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | Temporal TREM2 Pathway Modulation | 0.48 | 0.50 | ['TREM2', 'TYROBP'] | active | 2026-04-28 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | Multi-Target Microglial Metabolic Reprogramming | 0.48 | 0.50 | ['TREM2', 'APOE', 'CLU'] | active | 2026-04-28 | sda-2026-04-01-001 |
| hyp-sda-2026-04-01-0 | APOE-TREM2 Synergistic Modulation | 0.48 | 0.50 | ['APOE', 'TREM2'] | active | 2026-04-28 | sda-2026-04-01-001 |
| h-b7c58d63d6 | Brain Insulin Resistance and Metabolic Dysregulation | 0.48 | 0.52 | IRS1, INSR, IGF1R, AKT | proposed | 2026-04-28 | SDA-2026-04-28-cross-disease-synthesis |
| h-7856aa8a | SIRT1 Activator Therapy for Mitochondrial Epigenetic Dysregulation | 0.48 | 0.52 | SIRT1 pathway / NAD+ metabolism | proposed | 2026-04-26 | SDA-2026-04-16-gap-epigenetic-adpdals |
| h-00073ccb | DNA Methylation Clock Drift at Glial Promoters | 0.48 | 0.55 | DNA Methylation Clock | proposed | 2026-04-26 | SDA-2026-04-19-gap-epigenetic-comparative-ad-pd-als |
| h-e91a4dd06a | FSP1/CoQ10 Axis as GPX4-Independent Neuroprotective Pathway | 0.48 | 0.55 | FSP1 (NQO1/FDXR axis) / CoQ10 biosynthetic pathway | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-174000-6451afef-debate |
| h-2b95e7ad70 | Extracellular Vesicle Cargo Transfer | 0.48 | 0.40 | GW4869 target; EV biogenesis genes | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-170057-a2f72fd8-debate |
| h-dcd272ed1f | TH-neuron-restricted RGS6 rescue to test cell-autonomous therapeutic sufficiency | 0.48 | 0.36 | RGS6 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-145520-5692b02e-debate |
| h-41b54533e6 | A lower-dose 50-100 mg/day glial anti-inflammatory effect may occur, but is unli | 0.48 | 0.34 | IL6; TGFB1; AIF1; MAPK14; MAPK8; NFKB1 | proposed | 2026-04-26 | |
| h-896e71b129 | Platelet-Derived PDGF-BB Primes VSMCs for P2RY12 Upregulation | 0.48 | 0.42 | PDGFB, PDGFRB | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-a4d6154a |
| h-cb2065e26c | ISG Threshold Model Explains Acute vs Chronic Neurodegeneration Outcomes | 0.48 | 0.42 | USP18 / JAK/STAT pathway | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-fc60e018 |
| h-39c4d643 | FUS-ALS-Specific Ferroptosis Vulnerability Through NCOA4-Mediated Ferritinophagy | 0.48 | 0.48 | NCOA4 | proposed | 2026-04-17 | SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed |
| h-2e7eb2ea | Enteric Nervous System Prion-Like Propagation Blockade | 0.48 | 0.50 | TLR4, SNCA | archived | 2026-04-02 | SDA-2026-04-01-gap-20260401-225155 |
| h-5f3db142c9 | CX3CR1 PET with Nano-bodies for Microglial Surveillance State Mapping | 0.48 | 0.40 | CX3CR1 | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062039-3b945972 |
| h-826df660 | Optogenetic Control of Mitochondrial Transfer Networks | 0.48 | 0.40 | ChR2 | archived | 2026-04-03 | SDA-2026-04-01-gap-20260401231108 |
| h-SDA-2026-04-26-gap | Nuclear Export Sequestration and Cytoplasmic Depletion | 0.48 | 0.38 | NXF1 (TAP), THOC4 (AlyREF), DDX39B (UAP56); PHAX | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| h-SDA-2026-04-26-gap | Amyloid Plaque Clearance Triggers Downstream Reduction in Tau Kinase Activity, N | 0.48 | 0.27 | GSK3B, CDK5 | proposed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260417-033134-20519caa |
| h-d7b7189f | Ferroptosis as Context-Dependent and Motor Neuron-Subtype Selective | 0.47 | 0.25 | | proposed | 2026-04-18 | SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea |
| h-fe39641b | CHIP E3 Ligase Enhancement to Target Synaptic Proteins for Degradation | 0.47 | 0.47 | CHIP/STUB1 (STIP1 homology and U-box containing protein 1) | proposed | 2026-04-26 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-fdc381dee7 | Cerebral VSMC foam cells induce pericyte detachment via PDGF-BB/VEGF imbalance, | 0.47 | 0.50 | P2RY12 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-d7920f3b |
| h-var-afbf2de722 | VPS26A Subunit Enhancement to Stabilize Retromer Complex Assembly | 0.47 | 0.26 | VPS26A | proposed | 2026-04-27 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| h-f8b19743a2 | Moderate hyperoxia (1.5-2.0 ATA) optimally stabilizes HIF-1α to enhance VEGF-med | 0.47 | 0.48 | HIF1A | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-1d3f23017e | APOE4-associated inflammatory signaling amplifies SREBP2 activity in glia indepe | 0.47 | 0.46 | SREBF2 | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-f4c8357045 |
| h-e8569f838f | CD44-Mediated Src/PI3K/Akt Signaling Cascade | 0.47 | 0.55 | CD44, SRC, PI3K p85 (PIK3R1), MTOR | proposed | 2026-04-22 | SDA-2026-04-06-gap-pubmed-20260406-062118-e3613755 |
| h-286c496d01 | Mitochondrial Dysfunction Increasing Neuronal Vulnerability to TDP-43 Toxicity | 0.47 | 0.40 | MCU, CK1D, CSNK2A1, GSK3B, PARP1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1 |
| h-85cbb5cb4d | C1Q-Glia Cross-Talk in Vascular Dementia Pathogenesis | 0.47 | 0.40 | C1QA/C1QC | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062122-b65f8ebc |
| h-2e7fe1f16a | Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic Trapping) | 0.47 | 0.55 | ATP6V0C, ATP6V1 subunits (V-ATPase complex) | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-062150-5b7d1556 |
| h-8bd89d90 | Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption | 0.47 | 0.45 | PHB2 | archived | 2026-04-03 | SDA-2026-04-01-gap-9137255b |
| h-aging-h3-apoe-trem | APOE and TREM2 interact to modulate age-dependent microglial dysfunction | 0.47 | 0.72 | TREM2 | open | 2026-04-23 | aging-mouse-brain-2026-04-02 |
| h-c3354d65 | Cross-Tissue Communication Disruption | 0.47 | 0.41 | MULTIPLE | proposed | 2026-04-16 | SDA-2026-04-16-gap-bbb-tjp-20260416041707 |
| h-SDA-2026-04-26-gap | Sub-antidepressant Doses Suppress NLRP3 Inflammasome via P2X7 Receptor Blockade | 0.47 | 0.38 | P2RX7 (P2X7 receptor), NLRP3 inflammasome, IL-1beta | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb |
| h-7693c291 | RNA-Binding Competition Therapy for TDP-43 Cross-Seeding | 0.47 | 0.40 | TARDBP | archived | 2026-04-03 | SDA-2026-04-01-gap-9137255b |
| h-var-387b2bc276 | Gamma-Entrained PV Interneurons Enable Precision p-tau217-Guided lncRNA Exosome | 0.46 | 0.35 | PVALB, lncRNA-0021 | promoted | 2026-04-21 | SDA-2026-04-16-gap-pubmed-20260410-150509-76c40dac |
| h-f90320704e | TYROBP Network Hyperactivation Marks Point of No Return | 0.46 | 0.42 | TYROBP/SYK axis, MAPK/ERK signaling | proposed | 2026-04-22 | SDA-2026-04-06-gap-debate-20260406-062045-7a6cf14e |
| h-d504707b4e | Microglial Priming Window for HDAC1-Dependent DAM Transition | 0.46 | 0.52 | HDAC1 | proposed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062039-7ef9980b |
| h-d94e17c018 | Liquid-Liquid Phase Separation (LLPS) Saturation Partitioning Excludes Autophagy | 0.46 | 0.38 | SQSTM1/CALCOCO2 | proposed | 2026-04-21 | SDA-2026-04-08-gap-pubmed-20260406-041423-9c2c2ee3 |
| h-3f193704f2 | EC-II SST→PV Disinhibition Circuit Mechanism (Preclinical-Only Exploration) | 0.46 | 0.48 | GABAₐα5 subunit; PV+ basket cell network | proposed | 2026-04-28 | SRB-2026-04-28-h-var-b7e4505525 |
| h-e031e9fde6 | HBOT at 1.5 ATA for 90 days restores BBB integrity by upregulating claudin-5 and | 0.46 | 0.45 | CLDN5 | proposed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181340-8acb24dc-debate |
| h-a0c62d04e6 | BIN1-dependent trafficking defects determine whether post-Aβ tau missorting reso | 0.46 | 0.39 | BIN1,MAPT | proposed | 2026-04-25 | SDA-2026-04-25-gapdebate-98a600b3ed |
| h-342754e5ef | TSPO-Mediated TDP-43 Mitochondrial Import | 0.46 | 0.42 | TSPO (TSPO), TDP-43-TSPO protein-protein interaction | proposed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046 |